SciClone Pharmaceuticals, Inc. Patent applications |
Patent application number | Title | Published |
20120295840 | TREATMENT OF ASPERGILLUS INFECTIONS WITH ALPHA THYMOSIN PEPTIDES - A method for treating a human infected with | 11-22-2012 |
20110245316 | PREVENTION OR DELAY OF ONSET OF ORAL MUCOSITIS - The present invention provides a method for preventing or delaying the onset of oral mucositis, including the onset of ulcerative or severe OM, in a patient receiving cancer therapy. The method comprises administering to the patient an effective regimen of γ-D-glutamyl-L-tryptophan (SCV-07) over the course of therapy. The regimen, which includes scheduled doses of SCV-07 with respect to radiation exposure and/or chemotherapy, is effective for preventing or delaying the onset of OM. In accordance with the invention, the patient is more able to complete the planned course of cancer therapy (including chemotherapy and/or radiation therapy), by maintaining a sufficient nutritional state, and by avoiding the significant pain and discomfort associated with OM. | 10-06-2011 |
20110200558 | Treatment or Prevention of Hepatitis C with Immunomodulator Compounds - A method of treatment for treating or preventing hepatitis C (HepC) in a target subject, including administering to the target subject an effective amount of an immunomodulator compound of Formula A | 08-18-2011 |
20110117211 | Method of Treating or Preventing Tissue Deterioration, Injury or Damage Due to Disease of Mucosa - An immunomodulatory compound is utilized to treat mucosa disease. | 05-19-2011 |
20100330093 | TREATMENT OF MELANOMA WITH ALPHA THYMOSIN PEPTIDES IN COMBINATION WITH ANTIBODIES AGAINST CYTOTOXIC T LYMPHOCYTE-ASSOCIATED ANTIGEN 4 (CTLA4) - Melanoma or a metastasis thereof is treated in a human patient in a combination therapy which includes administering a melanoma-treating combination to a human melanoma patient during a treatment regimen, the combination including an alpha thymosin peptide and antibodies against cytotoxic T lymphocyte-associated antigen 4 (CTLA4). | 12-30-2010 |
20100317583 | TREATMENT OF MELANOMA WITH ALPHA THYMOSIN PEPTIDES IN COMBINATION WITH AN ANTINEOPLASTIC HEAT SHOCK APOPTOSIS ACTIVATOR (HSAA) - Melanoma or a metastasis thereof is treated in a human patient in a combination therapy which includes administering a melanoma-treating combination to a human melanoma patient during a treatment regimen, the combination including an alpha thymosin peptide and an antineoplastic heat shock apoptosis activator (HSAA) such as STA-4783 (and optionally an antineoplastic cytotoxic chemotherapeutic agent such as paclitaxel), and/or optionally one or more additional anti-melanoma agents. | 12-16-2010 |
20100285060 | ALPHA THYMOSIN PEPTIDES AS VACCINE ENHANCERS - The present invention provides methods of vaccination as well as pharmaceutical combinations and kits for enhancing vaccine effectiveness, including for immunodeficient or immunecompromised patients, including non-responders and low-responders to vaccination. As disclosed herein, the invention relates to administering a vaccine and a regimen of thymosin alpha peptide so as to provide higher antibody titers, speed the development of such antibody titers, and/or to provide for a longer duration of such antibody titers, thereby providing a greater protective effect. In another aspect, the invention allows for reducing a vaccine dose, such as an influenza vaccine dose, by administration of a thymosin peptide regimen. | 11-11-2010 |
20100267637 | TREATMENT OF MELANOMA WITH ALPHA THYMOSIN PEPTIDES IN COMBINATION WITH A KINASE INHIBITOR - Melanoma or a metastasis thereof is treated in a human patient in a combination therapy which includes administering a melanoma-treating combination to a human melanoma patient during a treatment regimen, the combination including an alpha thymosin peptide and a kinase inhibitor. | 10-21-2010 |
20100221274 | METHOD OF ADMINISTERING A THYMOSIN ALPHA 1 PEPTIDE - A Thymosin alpha 1 (TA1) peptide is administered to a patient in need of immune stimulation so as to substantially continuously maintain an immune stimulating-effective amount of the TA1 peptide in the patient. The administration method may be by continuous infusion. | 09-02-2010 |
20100204295 | TREATMENT OF ALLERGIC DISEASE WITH IMMUNOMODULATOR COMPOUNDS - A method of treatment for treating, preventing, inhibiting or reducing allergic disease or its effects in a subject, comprises administering to the subject an effective amount of an immunomodulator compound, which composes an aromatic or heterocyclic amino acid residue or a derivative thereof. Preferably, the immunomodulatory compound is a dipeptide which comprises a D- or L-tryptophan residue. | 08-12-2010 |
20100092499 | Alpha Thymosin Peptides as Cancer Vaccine Adjuvants - A pharmaceutical combination and method for enhancing cancer vaccine effectiveness in a subject, utilize an immune response-triggering cancer vaccine capable of eliciting an immune system response in a subject; and a vaccine effectiveness-enhancing amount of an alpha thymosin peptide, which enhances the immune system response in the subject, wherein the cancer vaccine and the alpha thymosin peptide can be administered separately or together. | 04-15-2010 |
20100086622 | METHOD OF TREATING OR PREVENTING TISSUE DETERIORATION, INJURY OR DAMAGE DUE TO DISEASE OF MUCOSA - An immunomodulatory compound is utilized to treat mucosa disease. | 04-08-2010 |
20100016211 | Treatment of Melanoma With Alpha Thymosin Peptides - A method of treating melanoma or a metastasis thereof in a human patient by administering a melanoma-treating effective amount of an alpha thymosin peptide to a human melanoma patient, wherein the human melanoma patient does not have a substantially elevated LDH blood level. | 01-21-2010 |
20090143313 | Treatment or Prevention of Hemorrhagic Viral Infections with Immunomodulator Compounds - An immunomodulatory compound is administered to a patient having, or at risk of a hemorrhagic viral infection. | 06-04-2009 |
20090088392 | TREATMENT OF MELANOMA - An immunomodulatory compound is administered to treat, prevent, inhibit, or reduce melanoma in a subject. | 04-02-2009 |
20090074815 | Immunomodulator Compounds as Vaccine Enhancers - A vaccination method utilizes a pharmaceutical combination for enhancing vaccine effectiveness. The method utilizes an immune response-triggering vaccine capable of stimulating production in an immunodefficicent animal of antibodies to a disease-causing agent foreign to the animal. As an adjuvant, a vaccine effectiveness-enhancing amount of an immunomodulator compound is administered, which enhances production and affinity of the antibodies in the animal, in response to the vaccine. | 03-19-2009 |
20080300166 | Treatment of Melanoma with Alpha Thymosin Peptides - A method of treating melanoma or a metastasis thereof in a human patient by administering a melanoma-treating effective amount of an alpha thymosin peptide to a human melanoma patient, wherein the human melanoma patient does not have a substantially elevated LDH blood level. | 12-04-2008 |